Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18670)	4/5/1998 6:49:00 PM
From: Proton	Respond to of 32384

Re: Tamoxifen v. Targretin The side-effect profile is important information, but this will get lost in the enthusiasm over the publicity we've seen this weekend. The truly critical information is the synergistic effect of Targretin with Tamoxifen, especially in prevention. Perhaps a biotech analyst on the Street will be savvy enough to understand that effect and initiate coverage of Ligand on that basis. It may be incumbent on Ligand's press relations people to create a media package on the synergistic effect (even health and science correspondents need to be spoon fed this stuff). Your points are, as they always are in the matter of the science, well taken. I trust that you and the other thread readers will see my remarks as coming from the angle of how the Street views news such as the Tamoxifen study, and not just the relative merits of the agents themselves. Pý

To: Henry Niman who wrote (18670)	4/6/1998 9:13:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

In financial papers (IBD and WSJ) as well as NY Times, I didn't see any coverage on the breast cancer prevention results (Tamoxifen is sold by ZEN). It's hard to see how this result could be a minus for LGND. They are involved with 2nd generation SERMs (Evista, Droloxifene, CP-366,156, and TSE424), all of which could be used in breast cancer prevention trials (as well as osteoporosis). The data on Tamoxifen sets the stage for new and improved versions (and there is much room for improvement), and I expect the above programs to accelerate, now that positive prevention data on Tamoxifen has been released. In addition to the SERMs, LGND has a big lead in the area of Rexinoids, and the breast cancer prevention data should spur LLY on. Animal data indicates that Targretin is as good as Tamoxifen, but with fewer side effects (does not stimulate endometrial tissues). Moreover, Targretin synergizes with Tamoxifen AND is effective in treating the side effects (stimulation of endometrial tissues) associated with tamoxifen. Moreover, as shown in LGND's pipeline table (at home.att.net ), LGND has two 2nd generation rexinoids (LGD1268 and LGD1324) ready for IND filing, and it's likely that these compounds will be more effective than Targretin. Future treatments of most diseases (as well as prevention) will rely on combinations of drugs, and LGND is well positioned in current and future drugs in the SERM and Rexinoid categories. Before the open, LGND's bid has been raised. Ask remains at 16 1/4.